Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study

被引:5
作者
Okamoto, Akinao [1 ]
Kanda, Yoshinobu [2 ,3 ]
Kimura, Shun-ichi [2 ]
Oyake, Tatsuo [4 ]
Tamura, Kazuo [5 ]
机构
[1] Fujita Hlth Univ, Dept Hematol, Div Hematol, Sch Med, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan
[2] Jichi Med Univ, Div Hematol, Saitama Med Ctr, Saitama, Japan
[3] Jichi Med Univ, Dept Med, Div Hematol, Saitama, Japan
[4] Iwate Med Univ, Dept Internal Med, Div Hematol & Oncol, Sch Med, Morioka, Iwate, Japan
[5] Fukuoka Univ, Res Promot Div, Fukuoka, Japan
关键词
Febrile neutropenia; Blood culture; Bacteria; Risk factors; Hematologic malignancy; EARLY ANTIFUNGAL THERAPY; ANTIBIOTIC-PROPHYLAXIS; BACTERIAL-INFECTIONS; CANCER; INDEX; RESISTANCE; FLUOROQUINOLONES; EPIDEMIOLOGY; CHEMOTHERAPY; METAANALYSIS;
D O I
10.1007/s12185-021-03183-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Bloodstream infection (BSI) is a frequent complication observed in patients with febrile neutropenia (FN). BSI risk factors and incidence vary depending on chemotherapy types and prophylactic antimicrobial agents. We clarified these issues by post-hoc analysis of a prospective clinical trial cohort for severe FN in hematological malignancy. Methods We performed an intention-to-treat analysis of 413 high-risk patients and 1272 blood culture sets. Results Overall, 356 patients (86.2%) developed FN, and 20.8% had BSI complications. Prophylactic antimicrobials did not prevent complications of FN and BSI, but the incidence of BSIs of Gram-negative (GN) bacteria was lower than in the non-prophylaxis group (23.8% vs. 56.7%). Multinational Association of Supportive Care in Cancer (MASCC) scores < 20 were significantly correlated with the incidence of BSI, whereas MASCC scores > 21 were not (41.7% vs. 17.2%). The only significant risk factors were hypotension and dehydration. axillary temperatures were higher in GN-caused BSIs than in Gram-positive-caused BSIs and in patients with negative blood culture results (38.7 degrees C vs. 38.2 degrees C vs. 38.0 degrees C). The higher the fever, the higher the incidence of BSI and GN bacteremia. Conclusions MASCC score and axillary temperature are strong predictors of BSI. Non-administration of prophylactic antimicrobials and GN-caused BSI are correlated.
引用
收藏
页码:472 / 482
页数:11
相关论文
共 32 条
[1]   Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia [J].
Ahn, Shin ;
Lee, Yoon-Seon ;
Lim, Kyung Soo ;
Lee, Jae-Lyun .
SUPPORTIVE CARE IN CANCER, 2013, 21 (08) :2303-2308
[2]   European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia [J].
Averbuch, Diana ;
Orasch, Christina ;
Cordonnier, Catherine ;
Livermore, David M. ;
Mikulska, Malgorzata ;
Viscoli, Claudio ;
Gyssens, Inge C. ;
Kern, Winfried V. ;
Klyasova, Galina ;
Marchetti, Oscar ;
Engelhard, Dan ;
Akova, Murat .
HAEMATOLOGICA, 2013, 98 (12) :1826-1835
[3]   PSEUDOMONAS BACTEREMIA - RETROSPECTIVE ANALYSIS OF 410 EPISODES [J].
BODEY, GP ;
JADEJA, L ;
ELTING, L .
ARCHIVES OF INTERNAL MEDICINE, 1985, 145 (09) :1621-1629
[4]   Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients [J].
Bow, Eric James .
CURRENT OPINION IN INFECTIOUS DISEASES, 2011, 24 (06) :545-553
[5]   Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia [J].
Bucaneve, G ;
Micozzi, A ;
Menichetti, F ;
Martino, P ;
Dionisi, MS ;
Martinelli, G ;
Allione, B ;
D'Antonio, D ;
Buelli, M ;
Nosari, AM ;
Cilloni, D ;
Zuffa, E ;
Cantaffa, R ;
Specchia, G ;
Amadori, S ;
Fabbiano, F ;
Deliliers, GL ;
Lauria, F ;
Foà, R ;
Del Favero, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (10) :977-987
[6]   C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms [J].
Combariza, Juan F. ;
Lombana, Milton ;
Pino, Luis E. ;
Arango, Marcos .
SUPPORTIVE CARE IN CANCER, 2015, 23 (04) :1009-1013
[7]   Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis [J].
Cruciani, M ;
Rampazzo, R ;
Malena, M ;
Lazzarini, L ;
Todeschini, G ;
Messori, A ;
Concia, E .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) :795-805
[8]   Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients [J].
Cruciani, M ;
Malena, M ;
Bosco, O ;
Nardi, S ;
Serpelloni, G ;
Mengoli, C .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4127-4137
[9]   Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis [J].
Engels, EA ;
Lau, J ;
Barza, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) :1179-1187
[10]   Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America [J].
Freifeld, Alison G. ;
Bow, Eric J. ;
Sepkowitz, Kent A. ;
Boeckh, Michael J. ;
Ito, James I. ;
Mullen, Craig A. ;
Raad, Issam I. ;
Rolston, Kenneth V. ;
Young, Jo-Anne H. ;
Wingard, John R. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (04) :427-431